EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

p38 Molecular Targeting for Next-Generation Multiple Myeloma Therapy

Mario Morales-Martínez, Mario I Vega iD

Cancers · 06.01.2024 · 16 (2) · 256

DOI: 10.3390/cancers16020256 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 06.01.2024. Verfasst von Mario Morales-Martínez und 1 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Signal Pathway in Cancer Laboratory, UIMEO, Oncology Hospital, Siglo XXI National Medical Center, Mexican Institute of Social Security (IMS…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resistance to therapy and disease progression are the main causes of mortality in most cancers. In particular, the development of resistance is an important limitation affecting the efficacy of therapeutic alternatives for cancer, including chemotherapy, radiotherapy, and immunotherapy. Signaling pathways are largely responsible for the mechanisms of resistance to cancer treatment and progression, and multiple myeloma is no exception. p38 mitogen-activated protein kinase (p38) is downstream of several signaling pathways specific to treatment resistance and progression. Therefore, in recent years, developing therapeutic alternatives directed at p38 has been of great interest, in order to reverse chemotherapy resistance and prevent progression. In this review, we discuss recent findings on the role of p38, including recent advances in our understanding of its expression and activity as well as its isoforms, and its possible clinical role based on the mechanisms of resistance and progression in multiple myeloma.

Schlagwörter

Stichwörter der Autor:innen

cancer progressionclinical implicationgene expressionmultiple myelomap38transcriptional factor

Autor:innen und Institutionen

  • Molecular Signal Pathway in Cancer Laboratory, UIMEO, Oncology Hospital, Siglo XXI National Medical Center, Mexican Institute of Social Security (IMSS), Mexico City 06720, Mexico.
  • Department of Medicine, Hematology-Oncology and Clinical Nutrition Division, Greater Los Angeles VA Healthcare Center, UCLA Medical Center, Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095, USA.

ORCID-Profile: Mario I Vega

Zitieren

APA

Morales-Martínez, M., & Vega, M. I. (2024). p38 Molecular Targeting for Next-Generation Multiple Myeloma Therapy. Cancers, 16(2), 256. https://doi.org/10.3390/cancers16020256

Vancouver

Morales-Martínez M, Vega MI. p38 Molecular Targeting for Next-Generation Multiple Myeloma Therapy. Cancers. 2024;16(2):256. doi:10.3390/cancers16020256

BibTeX
@article{MoralesMartnez2024,
  author = {Morales-Martínez, Mario and Vega, Mario I},
  title = {p38 Molecular Targeting for Next-Generation Multiple Myeloma Therapy},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {2},
  pages = {256},
  doi = {10.3390/cancers16020256}
}
Kostenlos starten →